Popular Trials
Checkpoint Inhibitor
Ipilimumab for Head and Neck Cancer
This trial is for patients with squamous cell carcinoma of the head and neck. It will test if it's possible to give ipilimumab, a cancer treatment, before surgery. The goal is to see if the patient's immune system responds to the treatment.
Behavioral Intervention
Cough and Expiratory Training for Pneumonia Risk after Head and Neck Cancer Treatment
This trial will test if exercising the muscles involved in coughing and swallowing can help reduce the risk of pneumonia for patients who have had radiation for head and neck cancer.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Popular Filters
Trials for Head And Neck Squamous Cell Carcinoma Patients
Platinum-based Chemotherapy
CACTUX for Head and Neck Cancer
This trial is testing a new cancer treatment called CACTUX. It's a combination of 3 drugs, and the investigators want to see if it's effective and has fewer side effects than the standard treatment.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Behavioural Intervention
Smoking Cessation Treatment for Head & Neck Cancer Patients
This trial is designed to study and compare the effectiveness of two types of counseling for cancer patients who want to quit smoking: Acceptance and Commitment Therapy (ACT) and Motivational and Behavioral Counseling (MBC).
Radiation
Radiation Therapy + Cetuximab for Head and Neck Cancer
This trial is comparing radiation therapy alone to radiation therapy given with the drug cetuximab to see if it is more effective in treating patients who have had surgery for locally advanced head and neck cancer.
Trials for Head And Neck Cancers Patients
Platinum-based Chemotherapy
CACTUX for Head and Neck Cancer
This trial is testing a new cancer treatment called CACTUX. It's a combination of 3 drugs, and the investigators want to see if it's effective and has fewer side effects than the standard treatment.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Behavioural Intervention
Smoking Cessation Treatment for Head & Neck Cancer Patients
This trial is designed to study and compare the effectiveness of two types of counseling for cancer patients who want to quit smoking: Acceptance and Commitment Therapy (ACT) and Motivational and Behavioral Counseling (MBC).
Radiation
Radiation Therapy + Cetuximab for Head and Neck Cancer
This trial is comparing radiation therapy alone to radiation therapy given with the drug cetuximab to see if it is more effective in treating patients who have had surgery for locally advanced head and neck cancer.
Trials for Metastatic Patients
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Monoclonal Antibodies
Pembrolizumab for Solid Tumors
This trial will study the changes in genes and immune cells of patients with solid tumors before and during treatment with pembrolizumab to see if there is a correlation with how well the patients respond to the treatment.
Taxane
Chemotherapy for Head and Neck Cancer
This trial is testing the efficacy and toxicity of two different chemotherapy treatments for head and neck squamous cell carcinoma (HNSCC), with the addition of a third arm testing a novel treatment approach for a subgroup with a very favorable prognosis.
Trials for PD-L1 Positive Patients
Monoclonal Antibodies
INBRX-106 + Pembrolizumab for Lung Cancer
This trial is studying a new drug to see if it is safe and effective at treating locally advanced or metastatic non small cell lung cancer when given in combination with pembrolizumab (Keytruda).
Checkpoint Inhibitor
Nivolumab + Relatlimab/Ipilimumab for Head and Neck Cancer
This trial is testing whether adding an anti-PD1 antibody to either an anti-CTLA4 antibody or an anti-LAG3 antibody will help improve the body's response to the tumor in people with resectable locally advanced HNSCC.
Trials for P16 Positive Patients
Alkylating agents
Reduced-Intensity Chemoradiotherapy for Oropharyngeal Cancer
This trial is testing a lower-intensity radiation and chemotherapy regimen to treat HPV-associated head and neck cancers. The goal is to see if it is as effective as the current standard of care while causing fewer side effects.
PD-1 Inhibitor
Pembrolizumab + Radiotherapy for Head and Neck Cancer
This trial is testing whether adding pembrolizumab to radiotherapy (with or without cisplatin) before and after surgery improves outcomes in people with newly diagnosed, resectable head and neck squamous cell carcinoma.
Phase 3 Trials
Radiation
Radiation Therapy + Cetuximab for Head and Neck Cancer
This trial is comparing radiation therapy alone to radiation therapy given with the drug cetuximab to see if it is more effective in treating patients who have had surgery for locally advanced head and neck cancer.
PD-1 Inhibitor
Pembrolizumab + Radiotherapy for Head and Neck Cancer
This trial is testing whether adding pembrolizumab to radiotherapy (with or without cisplatin) before and after surgery improves outcomes in people with newly diagnosed, resectable head and neck squamous cell carcinoma.
PI3K Inhibitor
Buparlisib + Chemotherapy for Head and Neck Cancer
This trial is testing a combination of two drugs, buparlisib and paclitaxel, for patients with head and neck cancer that has returned or spread after other treatments. Buparlisib is taken regularly to stop cancer cells from growing, and paclitaxel is given periodically to prevent them from multiplying. The goal is to see if this combination works better than using paclitaxel alone.
Trials With No Placebo
Platinum-based Chemotherapy
CACTUX for Head and Neck Cancer
This trial is testing a new cancer treatment called CACTUX. It's a combination of 3 drugs, and the investigators want to see if it's effective and has fewer side effects than the standard treatment.
PARP Inhibitor
Veliparib + Chemotherapy for Advanced Cancer
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Behavioural Intervention
Smoking Cessation Treatment for Head & Neck Cancer Patients
This trial is designed to study and compare the effectiveness of two types of counseling for cancer patients who want to quit smoking: Acceptance and Commitment Therapy (ACT) and Motivational and Behavioral Counseling (MBC).
Radiation
Radiation Therapy + Cetuximab for Head and Neck Cancer
This trial is comparing radiation therapy alone to radiation therapy given with the drug cetuximab to see if it is more effective in treating patients who have had surgery for locally advanced head and neck cancer.
View More Related Trials
Frequently Asked Questions
Introduction to head and neck cancer
What are the top hospitals conducting head and neck cancer research?
When it comes to advancing research and treatment options for head and neck cancer, several top hospitals are leading the way. In Boston, Dana Farber Cancer Institute is at the forefront with six active clinical trials focused on this complex condition. While they may not have any completed trials in their history specifically dedicated to head and neck cancer, their expertise in oncology positions them as a trusted institution for patients seeking cutting-edge treatment options. Similarly committed to innovation is Washington University School of Medicine in Saint Louis, where researchers are currently conducting five active head and neck cancer trials. Their dedication to finding new solutions for patients underscores the importance of ongoing research in this field.
In Houston, the University of Texas MD Anderson Cancer Center stands out as a renowned institution driving advancements in head and neck cancer care. With five ongoing clinical trials devoted exclusively to this disease, MD Anderson's multidisciplinary approach ensures that patients receive comprehensive, personalized treatment plans tailored to their specific needs. Meanwhile, at the University of Alabama at Birmingham (UAB), experts are actively engaged in four head and neck cancer trials aimed at improving outcomes for those affected by this challenging condition.
Finally, the UC San Diego Moores Cancer Center located in La Jolla rounds up our list of top hospitals contributing significantly towards combating head and neck cancers.. They too hold an impressive record with four current clinical trials focusing on enhancing treatments for these types of cancers; though like other institutions mentioned earlier ,they do not possess prior experiments under head or throat specialties but boasts state-of-the-art facilities ensuring patient access world-class resources while offering exceptional medical attention.
The collective efforts of these institutions highlight a commitment to pushing boundaries through innovative research and providing hope for individuals navigating their journey with head and neck cancer. By exploring novel therapies through rigorous clinical testing conducted by these esteemed hospitals across different regions nationwide we can look forward towards substantial improvements that will transform lives impacted by such conditions
Which are the best cities for head and neck cancer clinical trials?
When it comes to head and neck cancer clinical trials, several cities show promise in their research efforts. Chicago, Illinois leads the pack with 20 active trials focusing on treatments like Durvalumab and Pembrolizumab. Boston, Massachusetts closely follows with 19 ongoing studies investigating interventions such as Palbociclib and cetuximab. Additionally, Portland, Oregon and Houston, Texas both demonstrate significant contributions to the field with 14 active trials each exploring various treatment options including pralsetinib (BLU-667) and OSI-774. Finally, Los Angeles, California rounds out the list with 12 ongoing studies centered around interventions like cetuximab and GC4419 (avasopasem manganese) 90 mg. These cities provide hope for individuals battling head and neck cancer by offering access to cutting-edge clinical trials that may lead to improved outcomes and enhanced quality of life.
Which are the top treatments for head and neck cancer being explored in clinical trials?
The field of head and neck cancer research is making significant strides, with several cutting-edge treatments being investigated in clinical trials. Leading the pack is pembrolizumab, an immunotherapy drug that has shown promise in multiple studies. Another notable contender is cetuximab, a targeted therapy that specifically inhibits certain proteins involved in cancer growth. Additionally, chemoradiotherapy combinations are being explored as potential treatment options for head and neck cancer patients. These innovative approaches hold great potential to improve outcomes and provide hope for those affected by this challenging disease.
What are the most recent clinical trials for head and neck cancer?
Exciting advancements in the field of head and neck cancer research offer hope to patients seeking new treatment options. One such breakthrough is zimberelimab, a promising drug currently undergoing Phase 1 clinical trials for head and neck cancer. Additionally, venlafaxine, already approved for other conditions, is now being studied in Phase 4 trials as a potential therapy for this type of cancer. Another trial focuses on the use of pembrolizumab alone in participants with head and neck cancer, aiming to evaluate its effectiveness in Phase 2 studies. Furthermore, dermaprazole has shown promise during Phase 2 trials as a potential treatment option for this challenging disease. Lastly, SQZ-eAPC-HPV is being investigated through combined Phase 1 and Phase 2 trials to explore its efficacy against head and neck cancer. As these clinical trials progress, they bring us closer to improved outcomes and better quality of life for those affected by head and neck cancer
What head and neck cancer clinical trials were recently completed?
Recently completed clinical trials aimed at advancing treatment options for head and neck cancer have shown promising results. One notable trial, sponsored by the National Cancer Institute (NCI), concluded in September 2021. The study examined the efficacy of a novel therapy called Cetuximab in improving outcomes for patients with advanced head and neck squamous cell carcinoma. This breakthrough research offers hope for individuals battling this challenging form of cancer and underscores the ongoing efforts to find innovative solutions within the field of oncology.